Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Lowered by StockNews.com

Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Saturday.

SNDX has been the subject of several other research reports. Bank of America raised their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Citigroup raised their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price on the stock. JPMorgan Chase & Co. increased their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Stifel Nicolaus lifted their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $37.64.

Syndax Pharmaceuticals Trading Up 3.1 %

Syndax Pharmaceuticals stock opened at $16.09 on Friday. Syndax Pharmaceuticals has a 52 week low of $15.00 and a 52 week high of $25.34. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -4.43 and a beta of 0.92. The company’s 50-day moving average price is $18.60 and its two-hundred day moving average price is $19.98.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the prior year, the business earned ($0.73) EPS. Research analysts expect that Syndax Pharmaceuticals will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the last quarter. Sei Investments Co. increased its holdings in Syndax Pharmaceuticals by 2.5% in the first quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after buying an additional 991 shares during the last quarter. California State Teachers Retirement System raised its position in Syndax Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock valued at $1,822,000 after acquiring an additional 1,150 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in Syndax Pharmaceuticals in the second quarter valued at approximately $27,000. Finally, Values First Advisors Inc. bought a new stake in Syndax Pharmaceuticals in the third quarter worth approximately $30,000.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).